Supraspinally-administered agmatine attenuates the development of oral fentanyl self-administration

European Journal of Pharmacology

Volumn 587, Issue 1-3, 2008, Pages 135-140

  Wade, Carrie L ^a   Schuster, Daniel J ^a   Domingo, Kristine M ^a   Kitto, Kelley F ^a   Fairbanks, Carolyn A ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Intracerebroventricular; Neuroprotection; NMDA; NOS

Indexed keywords

AGMATINE; FENTANYL; OPIATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENUATION; BEHAVIOR; CONTROLLED STUDY; DRUG DEPENDENCE; DRUG MECHANISM; LOCOMOTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REINFORCEMENT; ROTAROD TEST;

AGMATINE; ANALGESICS, OPIOID; ANIMALS; AREA UNDER CURVE; DATA INTERPRETATION, STATISTICAL; FENTANYL; INJECTIONS, INTRAVENTRICULAR; INJECTIONS, SPINAL; MALE; MICE; MICE, INBRED ICR; MUSCULOSKELETAL EQUILIBRIUM; OPIOID-RELATED DISORDERS; REINFORCEMENT SCHEDULE; SELF ADMINISTRATION;

EID: 44149117451     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.04.007     Document Type: Article

References (44)

1. Aricioglu F., Ercil E., and Dulger G. Agmatine inhibits naloxone-induced contractions in morphine-dependent Guinea pig ileum. Ann. N. Y. Acad. Sci. 1009 (2003) 147-151
2. Aricioglu F., Paul I.A., and Regunathan S. Agmatine reduces only peripheral-related behavioral signs, not the central signs, of morphine withdrawal in nNOS deficient transgenic mice. Neurosci. Lett. 354 (2004) 153-157
3. Aricioglu-Kartal F., and Uzbay I.T. Inhibitory effect of agmatine on naloxone-precipitated abstinence syndrome in morphine dependent rats. Life Sci. 61 (1997) 1775-1781
4. Auguet M., Viossat I., Marin J.G., and Chabrier P.E. Selective inhibition of inducible nitric oxide synthase by agmatine. Jpn. J. Pharmacol. 69 (1995) 285-287
5. Benrath J., Brechtel C., Stark J., and Sandkuhler J. Low dose of S+-ketamine prevents long-term potentiation in pain pathways under strong opioid analgesia in the rat spinal cord in vivo. Br. J. Anaesth. 95 (2005) 518-523
6. Colpaert F.C., Tarayre J.P., Alliaga M., Bruins Slot L.A., Attal N., and Koek W. Opiate self-administration as a measure of chronic nociceptive pain in arthritic rats. Pain 91 (2001) 33-45
7. Demady D.R., Jianmongkol S., Vuletich J.L., Bender A.T., and Osawa Y. Agmatine enhances the NADPH oxidase activity of neuronal NO synthase and leads to oxidative inactivation of the enzyme. Mol. Pharmacol. 59 (2001) 24-29
8. Fairbanks C.A., and Wilcox G.L. Acute tolerance to spinally administered morphine compares mechanistically with chronically induced morphine tolerance. J. Pharmacol. Exp. Ther. 282 (1997) 1408-1417
9. Fairbanks C.A., Schreiber K.L., Brewer K.L., Yu C.G., Stone L.S., Kitto K.F., Nguyen H.O., Grocholski B.M., Shoeman D.W., Kehl L.J., Regunathan S., Reis D.J., Yezierski R.P., and Wilcox G.L. Agmatine reverses pain induced by inflammation, neuropathy, and spinal cord injury. Proc. Nat. Acad. Sci. USA 97 (2000) 10584-10589
10. Feng Y., LeBlanc M.H., and Regunathan S. Agmatine reduces extracellular glutamate during pentylenetetrazole-induced seizures in rat brain: a potential mechanism for the anticonvulsive effects. Neurosci. Lett. 390 (2005) 129-133
11. Galea E., Regunathan S., Eliopoulos V., Feinstein D.L., and Reis D.J. Inhibition of mammalian nitric oxide synthases by agmatine, an endogenous polyamine formed by decarboxylation of arginine. Biochem. J. 316 (1996) 247-249
12. Gilad G.M., and Gilad V.H. Brain polyamine stress response: recurrence after repetitive stressor and inhibition by lithium. J. Neurochem. 67 (1996) 1992-1996
13. Goracke-Postle C.J., Nguyen H.O., Stone L.S., and Fairbanks C.A. Release of tritiated agmatine from spinal synaptosomes. Neuroreport 17 (2006) 13-17
14. Goracke-Postle C.J., Overland A.C., Riedl M.S., Stone L.S., and Fairbanks C.A. Potassium- and capsaicin-induced release of agmatine from spinal nerve terminals. J. Neurochem. 102 (2007) 1738-1748
15. Haley T.J., and Mccormick W.G. Pharmacological effects produced by intracerebral injections of drugs in the conscious mouse. Br. J. Pharmacol. 12 (1957) 12-15
16. Haley J.E., Wilcox G.L., and Chapman P.F. The role of nitric oxide in hippocampal long-term potentiation. Neuron 8 (1992) 211-216 (Feb.)
17. Herman B.H., Vocci F., and Bridge P. The effects of NMDA receptor antagonists and nitric oxide synthase inhibitors on opioid tolerance and withdrawal. Medication development issues for opiate addiction. Neuropsychopharmacology 13 (1995) 269-293
18. Iyer R.K., Kim H.K., Tsoa R.W., Grody W.W., and Cederbaum S.D. Cloning and characterization of human agmatinase. Mol. Genet. Metabol. 75 (2002) 209-218
19. Kiss J.P. Role of nitric oxide in the regulation of monoaminergic neurotransmission. Brain Res. Bull. 52 (2000) 459-466
20. Kitto K.F., and Fairbanks C.A. Supraspinally administered agmatine prevents the development of supraspinal morphine analgesic tolerance. Eur. J. Pharmacol. 536 (2006) 133-137
21. Kitto K.F., Haley J.E., and Wilcox G.L. Involvement of nitric oxide in spinally mediated hyperalgesia in the mouse. Neurosci. Lett. 148 (1992) 1-5
22. Kivastik T., Rutkauskaite J., and Zharkovsky A. Nitric oxide synthesis inhibition attenuates morphine-induced place preference. Pharmacol. Biochem. Behav. 53 (1996) 1013-1015
23. Kolesnikov Y., Jain S., and Pasternak G.W. Modulation of opioid analgesia by agmatine. Eur. J. Pharmacol. 296 (1996) 17-22
24. Kupers R., and Gybels J. The consumption of fentanyl is increased in rats with nociceptive but not with neuropathic pain. Pain 60 (1995) 137-141
25. Li G., Regunathan S., Barrow C.J., Eshraghi J., Cooper R., and Reis D.J. Agmatine: an endogenous clonidine-displacing substance in the brain [see comments]. Science 263 (1994) 966-969
26. Ma Y.Y., Guo C.Y., Yu P., Lee D.Y., Han J.S., and Cui C.L. The role of NR2B containing NMDA receptor in place preference conditioned with morphine and natural reinforcers in rats. Exp. Neurol. 200 (2006) 343-355
27. Martin S., Lyupina Y., Crespo J.A., Gonzalez B., Garcia-Lecumberri C., and Ambrosio E. Genetic differences in NMDA and D1 receptor levels, and operant responding for food and morphine in Lewis and Fischer 344 rats. Brain Res. 973 (2003) 205-213
28. Mistry S.K., Burwell T.J., Chambers R.M., Rudolph-Owen L., Spaltmann F., Cook W.J., and Morris Jr. S.M. Cloning of human agmatinase. An alternate path for polyamine synthesis induced in liver by hepatitis B virus. Am. J. Phys. - Gastrointest Liver Physiol. 282 (2002) G375-G381
29. Morgan A.D., Campbell U.C., Fons R.D., and Carroll M.E. Effects of agmatine on the escalation of i.v. cocaine and fentanyl self-administration in rats. Pharmacol. Biochem. Behav. 72 (2002) 873-880
30. Myers W.A., Churchill J.D., Muja N., and Garraghty P.E. Role of NMDA receptors in adult primate cortical somatosensory plasticity. J. Comp. Neurol. 418 (2000) 373-382
31. Nguyen H.O., Goracke-Postle C.J., Kaminski L.L., Overland A.O., Morgan A.D., and Fairbanks C.A. Neuropharmacokinetic and dynamic studies of agmatine. Ann. N. Y. Acad. Sci. 1009 (2003) 82-105
32. Ohno M., Frankland P.W., and Silva A.J. A pharmacogenetic inducible approach to the study of NMDA/alphaCaMKII signaling in synaptic plasticity. Curr. Biol. 12 (2002) 654-656
33. Papp M., Gruca P., and Willner P. Selective blockade of drug-induced place preference conditioning by ACPC, a functional NDMA-receptor antagonist. Neuropsychopharmacology 27 (2002) 727-743
34. Parsons C.G., Danysz W., Bartmann A., Spielmanns P., Frankiewicz T., Hesselink M., Eilbacher B., and Quack G. Amino-alkyl-cyclohexanes are novel uncompetitive NMDA receptor antagonists with strong voltage-dependency and fast blocking kinetics: in vitro and in vivo characterization. Neuropharmacology 38 (1999) 85-108
35. Parsons C.G., Danysz W., and Quack G. Memantine is a clinically well tolerated N-methyl-d-aspartate (NMDA) receptor antagonist-a review of preclinical data. Neuropharmacology 38 (1999) 735-767
36. Piletz J.E., May P.J., Wang G., and Zhu H. Agmatine crosses the blood-brain barrier. Ann. N. Y. Acad. Sci. 1009 (2003) 64-74
37. Raasch W., Schafer U., Qadri F., and Dominiak P. Agmatine, an endogenous ligand at imidazoline binding sites, does not antagonize the clonidine-mediated blood pressure reaction. Br. J. Pharmacol. 135 (2002) 663-672
38. Reis D.J., and Regunathan S. Agmatine: an endogenous ligand at imidazoline receptors may be a novel neurotransmitter in brain. J. Auton. Nerv. Sys. 72 (1998) 80-85
39. 2+ fluxes. Br. J. Pharmacol. 101 (1990) 178-182
40. Roberts, J.C., 2007. Pharmacokinetics, pharmacodynamics and transport of agmatine in the CNS. Ph.D. Thesis Dissertation.
41. Roberts J.C., Grocholski B.M., Kitto K.F., and Fairbanks C.A. Pharmacodynamic and pharmacokinetic studies of agmatine after spinal administration in the mouse. J. Pharmacol. Exp. Ther. 314 (2005) 1226-1233
42. Sahraei H., Poorheidari G., Foadaddini M., Khoshbaten A., Asgari A., Noroozzadeh A., Ghoshooni H., Firoozabadi S.H., and Zarrindast M.R. Effects of nitric oxide on morphine self-administration in rat. Pharmacol. Biochem. Behav. 77 (2004) 111-116
43. Semenova S., Danysz W., and Bespalov A. Low-affinity NMDA receptor channel blockers inhibit acquisition of intravenous morphine self-administration in naive mice. Eur. J. Pharmacol. 378 (1999) 1-8
44. Yang X.C., and Reis D.L. Agmatine selectively blocks the N-methyl-d-aspartate subclass of glutamate receptor channels in rat hippocampal neurons. J. Pharmacol. Exp. Ther. 288 (1999) 544-549